We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

This study is currently recruiting participants.
Verified October 2017 by Catalyst Pharmaceuticals, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02970162
First Posted: November 21, 2016
Last Update Posted: October 4, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Catalyst Pharmaceuticals, Inc.
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2017
  Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)